QIAGEN unveils new rapid QIAstat-Dx panel, entering into bloodstream infection syndromic testing
QIAGEN introduces the CE-IVDR-certified QIAstat-Dx BCID GPF Plus AMR Panel, enabling rapid identification of bloodstream infection pathogens and resistance markers within an hour, expanding their syndromic testing portfolio.
QIAGEN has expanded into syndromic testing for bloodstream infections with the launch of the CE-IVDR-certified QIAstat-Dx BCID GPF Plus AMR Panel, according to a release.
The QIAstat-Dx BCID GPF Plus AMR Panel enables laboratories to identify 20 gram-positive bacterial and fungal pathogen targets (GPF) and 10 antimicrobial resistance (AMR) markers from positive blood cultures and pure colonies in about one hour. This launch expands the QIAstat-Dx portfolio beyond respiratory, gastrointestinal and meningitis/encephalitis testing into bloodstream infection applications.
QIAstat-Dx integrates sample preparation, molecular testing and data analysis into a single workflow. The systems are available in more than 100 countries, with more than 5,200 instruments placed worldwide as of the end of 2025.
